Clene Inc. Advances Toward FDA Submission for ALS Therapy with Promising Q2 2025 Results
Clene Inc. reports significant progress in its Q2 2025 results, targeting a year-end NDA submission for its ALS therapy, CNM-Au8, with sufficient cash runway into Q1 2026.
Clene Inc. (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, has announced its Q2 2025 financial results, revealing a strategic focus on advancing its lead candidate, CNM-Au8, for the treatment of amyotrophic lateral sclerosis (ALS). The company has confirmed it has enough financial resources to sustain operations into Q1 2026, ensuring continued progress toward its goal of submitting a New Drug Application (NDA) to the FDA by the end of 2025 under the accelerated approval pathway.
The upcoming quarter is pivotal for Clene, as it plans to meet with the FDA to discuss survival data from its CNM-Au8 trials. Additionally, the company is preparing to analyze neurofilament light biomarker data from the NIH-sponsored Expanded Access Program, with results expected in Q4. These analyses are crucial for supporting the NDA submission, offering hope for a new therapeutic option for the ALS community.
CNM-Au8 represents a novel approach to treating neurodegenerative diseases by targeting mitochondrial function and the NAD pathway, aiming to reduce oxidative stress and improve neuronal survival. The therapy's potential impact on ALS, a condition with limited treatment options, underscores the importance of Clene's ongoing research and development efforts.
For more details on Clene's Q2 2025 results and its ALS therapy development, visit https://ibn.fm/qTCmZ.
Clene's commitment to addressing unmet medical needs in neurodegenerative diseases highlights the significance of its work, not only for patients and families affected by ALS but also for the broader medical and scientific community seeking innovative treatments.